Follicular lymphoma: A historical overview

Leukemia and Lymphoma

Volumn 48, Issue 2, 2007, Pages 232-243

  van Besien, Koen ^a   Schouten, Harry ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACEPROMAZINE; ANTHRACYCLINE DERIVATIVE; BIOLOGICAL RESPONSE MODIFIER; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN IDIOTYPE; INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B7; MONOCLONAL ANTIBODY CD22; MONOCLONAL ANTIBODY HLA DR; NUCLEOSIDE DERIVATIVE; OBLIMERSEN; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; PROTEIN BCL 2; RITUXIMAB; TENIPOSIDE; TOSITUMOMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 14; CHROMOSOME 18; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG TARGETING; FOLLICULAR LYMPHOMA; GENE REARRANGEMENT; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE RESPONSE; MICROSCOPY; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNITED STATES; UNSPECIFIED SIDE EFFECT; ARTICLE; HISTORY;

HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LYMPHOMA, FOLLICULAR;

EID: 34247868049     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601059746     Document Type: Review

References (108)

1. Virchow, R. Cellular Pathology as Based Upon Physiological and Pathological Pathology,, Robert M. Dewitt, New York
2. Cohnheim, J. Ein Fall von Pseudoleukämie. Virchows Arch, 33, pp. 451-454.
3. Magrath, I. T. (1997) Historical perspective: The evolution of modern concepts of biology and management. The Non-Hodgkin's Lymphomas,, pp. 47-76. Arnold, London
4. Brill, N. E., Baehr, G. and Rosenthal, N. (1925) Generalized giant lymph follicle hyperplasia of lymph nodes and spleen. JAMA, 84, pp. 668-670.
5. Symmers, D. (1927) Follicular lymphadenopathy with splenomegaly. Arch Pathol Lab Med, 3, p. 820.
6. Jackson, H. (1937) The classification and prognosis of Hodgkin's disease and allied disorders. Surg Gynecol Obstet, p. 465.
7. Gall, E. A., Morrison, H. R. and Scott, A. T. (1941) The follicular type of malignant lymphoma: A survey of 63 cases. Ann Int Med, 14, pp. 2073-2083.
8. Ryan, D. H. and Cohen, H. J. (2000) Bone marrow aspiration and morphology. Hematology, Basic Principles and Practice,, pp. 2460-2468. Churchill Livingstone, New York
9. Rappaport, H., Winter, W. J. and Hicks, E. B. (1956) Follicular lymphoma: A reevaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer, 9, pp. 792-821.
10. Bosga-Bouwer, A. G., van den, B. A., Haralambieva, E., de, J. D., Boonstra, R. and Kluin, P. (2006) Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?. Hum Pathol, 37, pp. 528-533.
11. Gall, E. A. and Mallory, T. B. (1942) Malignant lymphoma, a clinico-pathologic survey of 618 cases. Am J Pathol, 18, pp. 381-429.
12. Biagi, J. J. and Seymour, J. F. (2002) Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood, 99, pp. 4265-4275.
13. Seligmann, M., Grouet, J. C. and Preud'homme, C. (1977) The immunological diagnosis of human leukemias and lymphomas. An overview. Immunological Diagnosis of Leukemias and Lymphomas, pp. 1-16. Springer Verlag, Berlin
14. Jaffe, E. S., Shevach, E. M., Frank, M. M., Berard, C. W. and Green, I. (1974) Nodular lymphoma - evidence for origin from follicular B lymphocytes. N Engl J Med, 290, pp. 813-819.
15. Glick, A. D., Leech, J. H., Waldron, J. A., Flexner, J. M., Horn, R. G. and Collins, R. D. (1975) Malignant lymphomas of follicular center cell origin in man. II. Ultrastructural and cytochemical studies. J Nat Cancer Inst, 54, pp. 23-36.
16. Leech, J. H., Glick, A. D., Waldron, J. A., Flexner, J. M., Horn, R. G. and Collins, R. D. (1975) Malignant lymphomas of follicular center cell origin in man. I. Immunologic studies. J Nat Cancer Inst, 54, pp. 11-21.
17. Harris, N. L., Nadler, L. M. and Bhan, A. K. (1984) Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities. Am J Pathol, 117, pp. 262-272.
18. Yunis, J. J., Oken, M. M., Kaplan, M. E., Ensrud, K. M., Howe, R. R. and Theologides, A. (1982) Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med, 307, pp. 1231-1236.
19. Horsman, D. E., Gascoyne, R. D., Coupland, R. W., Coldman, A. J. and Adomat, S. A. (1995) Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma. Am J Clin Pathol, 103, pp. 472-478.
20. Knutsen, T. (1997) Cytogenetic mechanisms in the pathogenesis and progression of follicular lymphoma. Cancer Surv, 30, pp. 163-192.
21. Cleary, M. L. and Sklar, J. (1985) Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA, 82, pp. 7439-7443.
22. Korsmeyer, S. J., McDonnell, T. J., Nunez, G., Hockenbery, D. and Young, R. (1990) bcl-2: B cell life, death and neoplasia. Curr Top Microbiol Immunol, 166, pp. 203-207.
23. McDonnell, T. J., Nunez, G., Platt, F. M., Hockenberry, D., London, L. and McKearn, J. P. (1990) Deregulated bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol Cell Biol, 10, pp. 1901-1907.
24. McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U. and McKearn, J. P. (1989) bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell, 57, pp. 79-88.
25. McDonnell, T. J. and Korsmeyer, S. J. (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature, 349, pp. 254-256.
26. Hoglund, M., Sehn, L., Connors, J. M., Gascoyne, R. D., Siebert, R. and Sall, T. (2004) Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer, 39, pp. 195-204.
27. De Jong, D. (2005) Molecular pathogenesis of follicular lymphoma: A cross talk of genetic and immunologic factors. J Clin Oncol, 23, pp. 6358-6363.
28. Quesada, J. R., Hawkins, M., Horning, S. J., Alexanian, R., Borden, T. and Merigan, T. (1984) A collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med, 77, pp. 427-432.
29. Bahler, D. W. and Levy, R. (1992) Clonal evolution of a follicular lymphoma: Evidence for antigen selection. Proc Natl Acad Sci USA, 89, pp. 6770-6774.
30. Zelenetz, A. D., Campbell, M. J., Bahler, D. W., Takahashi, S., Oren, R. and Esserman, L. (1991) Follicular lymphoma: A model of lymphoid tumor progression in man. Ann Oncol, 2, pp. 115-122.
31. Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D. and Chan, W. C. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 351, pp. 2159-2169.
32. Farinha, P., Masoudi, H., Skinnider, B. F., Shumansky, K., Spinelli, J. J. and Gill, K. (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 106, pp. 2169-2174.
33. McLaughlin, P. (2002) Progress and promise in the treatment of indolent lymphomas. Oncologist, 7, pp. 217-225.
34. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O. and Arranz-Saez, R. (2004) Follicular lymphoma international prognostic index. Blood, 104, pp. 1258-1265.
35. Rohatiner, A. Z., Gregory, W. M., Peterson, B., Borden, E., Solal-Celigny, P. and Hagenbeek, A. (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol, 23, pp. 2215-2223.
36. Schouten, H. C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H. and Johnson, H. E. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol, 21, pp. 3918-3927.
37. Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M. and Miller, T. P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol, 23, pp. 8447-8452.
38. Paryani, S. B., Hoppe, R. T., Cox, R. S., Colby, T. V. and Kaplan, H. S. (1984) The role of radiation therapy in the management of stage III follicular lymphomas. J Clin Oncol, 2, pp. 841-848.
39. McLaughlin, P., Fuller, L. M., Velasquez, W. S., Sullivan-Halley, J. A., Butler, J. J. and Cabanillas, F. (1986) Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer, 58, pp. 1596-1602.
40. Monfardini, S., Banfi, A., Bonadonna, G., Rilke, F., Milani, F. and Valagussa, P. (1980) Improved 5-year survival after combined radiotherapy-chemotherapy for Stage I-II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 6, pp. 125-134.
41. Peters, M. (1963) The contribution of radiation therapy in the control of early lymphomas. Am J Roentgenol Radium Ther Nucl Med, 90, pp. 956-967.
42. Cox, J. D., Komaki, R., Kun, L. E., Wilson, J. F. and Greenberg, M. (1981) Stage III nodular lymphoreticular tumors (non-Hodgkin's lymphoma): Results of central lymphatic irradiation. Cancer, 47, pp. 2247-2252.
43. Glatstein, E., Fuks, Z., Goffinet, D. R. and Kaplan, H. S. (1976) Non-Hodgkin's lymphomas of stage III extent. Is total lymphoid irradiation appropriate treatment?. Cancer, 37, pp. 2806-2812.
44. Ha, C. S., Kong, J. S., Tucker, S. L., McLaughlin, P., Wilder, R. B. and Hess, M. A. (2003) Central lymphatic irradiation for stage I-III follicular lymphoma: Report from a single-institutional prospective study. Int J Radiat Oncol Biol Phys, 57, pp. 316-320.
45. Frei, E. (1984) Acute leukemia in children. Model for the development of scientific methodology for clinical therapeutic research in cancer. Cancer, 53, pp. 2013-2025.
46. Frei III, E. (1985) Curative cancer chemotherapy. Cancer Res, 45, pp. 6523-6537.
47. Horning, S. J. (1994) Treatment approaches to the low-grade lymphomas. Blood, 83, pp. 881-884.
48. Young, R. C., Longo, D. L., Glatstein, E., Ihde, D. C., Jaffe, E. S. and DeVita Jr, V. T. (1988) The treatment of indolent lymphomas: Watchful waiting vs. aggressive combined modality treatment. Semin Hematol, 25, pp. 11-16.
49. Ardeshna, K. M., Smith, P., Norton, A., Hancock, B. W., Hoskin, P. J. and MacLennan, K. A. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet, 362, pp. 516-522.
50. Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haioun, C. and Moreau, P. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no treatment-policy, prednimustine, or interferon alfa: A randomized study from the groupe d'etude des lymphomes folliculaires. J Clin Oncol, 15, pp. 1110-1117.
51. Denham, J. W., Denham, E., Dear, K. B. and Hudson, G. V. (1996) The follicular non-Hodgkin's lymphomas. I. The possibility of cure. Eur J Cancer A, 32, pp. 470-479.
52. Kimby, E., Bjorkholm, M., Gahrton, G., Glimelius, B., Hagberg, H. and Johansson, B. (1994) Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol, 5, pp. 67-71.
53. Peterson, B. A., Petroni, G. R., Frizzera, G., Barcos, M., Bloomfield, C. D. and Nissen, N. I. (2003) Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the Cancer and Leukemia Group B. J Clin Oncol, 21, pp. 5-15.
54. Coiffier, B., Neidhardt-Berard, E. M., Tilly, H., Belanger, C., Bouabdallah, R. and Haioun, C. (1999) Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol, 10, pp. 1191-1197.
55. Hagenbeek, A., Eghbali, H., Monfardini, S., Vitolo, U., Hoskin, P. J. and De Wolf-Peeters, C. (2006) Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol, 24, pp. 1590-1596.
56. Krim, M. (1980) Towards tumor therapy with interferons, Part 2: Interferons: In vivo effects. Blood, 55, pp. 875-884.
57. Priestman, T. J. (1979) Interferon: An anti-cancer agent?. Cancer Treat Rev, 6, pp. 223-237.
58. Borden, E. C. (1979) Interferons: Rationale for clinical trials in neoplastic disease. Ann Intern Med, 91, pp. 472-479.
59. Gutterman, J. U., Blumenschein, G. and Alexanian, R. (1980) leucocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med, 93, pp. 399-406.
60. Foon, K. A., Sherwin, S. A., Abrams, P. G., Longo, D. L., Fer, M. F. and Stevenson, H. C. (1984) Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med, 311, pp. 1148-1152.
61. O'Connell, M. J., Colgan, J. P., Oken, M. M., Ritts Jr, R. E., Kay, N. E. and Itri, L. M. (1986) Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphoma and chronic lymphocytic leukemia. An ECOG pilot study. J Clin Oncol, 4, pp. 128-136.
62. Wagstaff, J., Loynds, P. and Crowther, D. (1986) A phase II study of human recombinant DNA-a2 interferon in patients with low-grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol, 18, pp. 54-58.
63. Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C. and Leporrier, M. (1993) Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med, 329, pp. 1608-1614.
64. Smalley, R. V., Andersen, J. W., Hawkins, M. J., Bhide, V., O'Connell, M. J. and Oken, M. M. (1992) Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med, 327, pp. 1336-1341.
65. Andersen, J. W. and Smalley, R. V. (1993) Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: Five-year follow-up. N Engl J Med, 329, pp. 1821-1822.
66. Unterhalt, M., Hermann, R., Koch, P., Trumper, L., Bodenstein, H. and Dietzfelbinger, H. (1996) Long term interferon α maintenance prolongs remission duration in advanced low grade lymphoma and is related to the efficacy of initial cytoreductive therapy. p. 453a. Anonymous
67. Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C. and Leporrier, M. (1993) Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med, 329, pp. 1608-1614.
68. Aviles, A., Duque, G., Talavera, A. and Guzman, R. (1996) Interferon α2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma, 20, pp. 495-499.
69. Hagenbeek, A., Carde, P., Meerwaldt, J. H., Somers, R., Thomas, J. and De Bock, R. (1998) Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol, 16, pp. 41-47.
70. Arranz, R., Garcia-Alfonso, P., Sobrino, P., Zamora, P., Carrion, R. and Garcia-Larana, J. (1998) Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization. J Clin Oncol, 16, pp. 1538-1546.
71. Fisher, R. I., Dana, B. W., LeBlanc, M., Kjeldsberg, C., Forman, J. D. and Unger, J. M. (2000) Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol, 18, pp. 2010-2016.
72. Rohatiner, A., Radford, J., Deakin, D., Earl, H., Love, S. B. and Price, O. (2001) A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer, 85, pp. 29-35.
73. Peterson, B. A., Petroni, G. R. and Oken, M. M. (1997) Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: An intergroup phase III trial (CALGB 8691 and EST 7486). p. 14a. Proc Am Soc Clin Oncol
74. Cheson, B. D. (2000) The curious case of the baffling biological. J Clin Oncol, 18, pp. 2007-2009.
75. Tse, W. W., Lazarus, H. M. and van Besien, K. (2004) Stem cell transplantation in follicular lymphoma: Progress at last?. Bone Marrow Transplant, 34, pp. 929-938.
76. van Besien, K., Loberiza, F. R., Bajorunaite, R., Armitage, J. O., Bashey, A. and Burns, L. J. (2003) Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood, 102, pp. 3521-3529.
77. Corradini, P., Ladetto, M., Zallio, F., Astolfi, M., Rizzo, E. and Sametti, S. (2004) Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol, 22, pp. 1460-1468.
78. Bierman, P. J., Sweetenham, J. W., Loberiza, F. M., Zhang, M. J., Ballen, K. K. and Bashey, A. (2003) Syngeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation. J Clin Oncol, pp. 3744-3753.
79. Lenz, G., Dreyling, M., Schiegnitz, E., Forstpointner, R., Wandt, H. and Freund, M. (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma - results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood, 104, pp. 2667-2674.
80. Deconinck, E., Foussard, C., Milpied, N., Bertrand, P., Michenet, P. and Cornillet-LeFebvre, P. (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS. Blood, 105, pp. 3817-3823.
81. Sebban, C., Mounier, N., Brousse, N., Belanger, C., Brice, P. and Haioun, C. (2006) Standard chemotherapy with interferon compared to CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the GELA. Blood, 108, pp. 2540-2544.
82. Dillman, R. O. (2001) The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy. Curr Pharm Biotechnol, 2, pp. 293-300.
83. Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N. and Kufe, D. W. (1980) Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res, 40, pp. 3147-3154.
84. Grillo-Lopez, A. J. (2000) Rituximab: An insider's historical perspective. Semin Oncol, 27, pp. 9-16.
85. McLaughlin, P., Hagemeister, F. B. and Grillo-Lopez, A. J. (1999) Rituximab in indolent lymphoma: The single-agent pivotal trial. Semin Oncol, 26, pp. 79-87.
86. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E. and Catalano, J. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, pp. 1417-1423.
87. Gandhi, M. K. and Marcus, R. E. (2005) Follicular lymphoma: Time for a re-think?. Blood Rev, 19, pp. 165-178.
88. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E. and Schmits, R. (2005) Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood, 106, pp. 3725-3732.
89. Herold, M., Pasold, R., Srock, S., Neser, S., Niederwieser, D. and Neubauer, A. (2004) Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). ASH Annual Meeting Abstr, 104, p. 584.
90. Salles, G. A., Foussard, C., Nicolas, M., Franck, M., Chantal, D. and Thierry, L. (2004) Rituximab Added {alpha}IFN + CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: To first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. ASH Annual Meeting Abstr, 104, p. 160.
91. Buske, C. and Hiddemann, W. (2006) Rituximab maintenance therapy in indolent NHL: A clinical review. Leuk Res, 30, pp. S11-S15.
92. Khouri, I. F., Saliba, R. M., Hosing, C., Okoroji, G. J., Acholonu, S. and Anderlini, P. (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol, 23, pp. 2240-2247.
93. Hoerr, A. L., Gao, F., Hidalgo, J., Tiwari, D., Blum, K. A. and Mathews, V. (2004) Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol, 22, pp. 4561-4566.
94. Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J. and Stockerl-Goldstein, K. E. (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 103, pp. 777-783.
95. Gordon, L. I., Witzig, T., Molina, A., Czuczman, M., Emmanouilides, C. and Joyce, R. (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymph, 5, pp. 98-101.
96. Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W. and Zasadny, K. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 352, pp. 441-449.
97. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W. and Milik, A. W. (1996) Iodine-131-anti B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol, 14, pp. 1974-1981.
98. Czuczman, M. S., Thall, A., Witzig, T. E., Vose, J. M., Younes, A. and Emmanouilides, C. (2005) Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol, 23, pp. 4390-4398.
99. DeNardo, G. L. (2005) Concepts in radioimmunotherapy and immunotherapy: radioimmunotherapy from a Lym-1 perspective. Semin Oncol, 32, pp. S27-S35.
100. Leonard, J. P., Coleman, M., Ketas, J., Ashe, M., Fiore, J. M. and Furman, R. R. (2005) Combination antibody therapy with epratuzumab and rituximab in relapsed/refractory non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 5044-5051.
101. Hsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M. and Syrengelas, A. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood, 89, pp. 3129-3135.
102. Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A. and Pennington, R. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med, 5, pp. 1171-1177.
103. Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F. and Stefano, F di (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol, 18, pp. 1812-1823.
104. Klasa, R. J. (2004) Targeting the proapoptotic factor bcl-2 in non-Hodgkin's lymphoma. Oncology, 18, pp. 25-31.
105. Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S. and Wright, R. D. (2004) Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 305, pp. 1466-1470.
106. Polo, J. M., Dell'Oso, T., Ranuncolo, S. M., Cerchietti, L., Beck, D. and Silva, G F Da (2004) Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med, 10, pp. 1329-1335.
107. Lenz, G., Dreyling, M., Unterhalt, M. and Hiddemann, W. (2005) In reply: should we transplant patients with indolent lymphoma. J Clin Oncol, 23, pp. 6264-6266.
108. Liu, Q., Fayad, L., Cabanillas, F., Hagemeister, F. B., Ayers, G. D. and Hess, M. (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol, 24, pp. 1582-1589.